ArticleHemaSphere2026

First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

Umberto Vitolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.